Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:4 Number:171 ISSN#:2564-2537
ACE Report #4963
Ace Report Cover General Orthopaedics

ISAKOS: Similiar Results with PRP and HA Injections for Early Knee Osteoarthritis

How to Cite

OrthoEvidence. ISAKOS: Similiar Results with PRP and HA Injections for Early Knee Osteoarthritis. ACE Report. 2013;2(4):171. Available from: https://myorthoevidence.com/AceReport/Report/4963

Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

PRP Injections Versus Viscosupplementation for Early Knee Osteoarthritis: A Randomized Double-Blind Trial

Contributing Authors: E Kon G Filardo A Di-Martino S Patella B Di Matteo L Merli L Andriolo F Tentoni Marcacci M Marcacci

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.


192 patients, older than 18 years, with chronic pain or swelling of knee and degeneration of the joint were randomized to be treated either with platelet rich plasma (PRP) or viscosupplementation (Hyaluronic Acid-HA) injections. To compare both treatment modalities for knee chondropathy or early osteoarthritis (OA), a year of clinical evaluation demonstrated that both groups had significant improv...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.